Agilent Technologies, Inc. news

Agilent Technologies Inc. (NYSE: A) today announced that Dr. Jeffrey Gordon has received an Agilent Thought Leader Award in support of his pioneering research into the mutually beneficial relationship between the human body and the tens of trillions of microbes that inhabit the gastrointestinal tract.

Dr. Gordon directs the Center for Genome Sciences and Systems Biology at Washington University School of Medicine in St. Louis. The award, which includes funding and c

Agilent Technologies Inc. (NYSE: A) today named Dr. Mitchell Guttman the winner of its 2015 Early Career Professor Award. The award, now in its seventh year, recognizes one early career professor for his or her exceptional, original research contributions and outstanding potential for future research. Dr. Guttman was selected from a global pool of professors contributing to the understanding and use of RNA-based technologies for genome editing and control.

Dr. Guttman is assistant pro

Jay Teich, former Seahorse Bioscience CEO, received the first-ever CEO Innovator Award from the Society for Redox Biology and Medicine (SFRBM). This international award recognizes industry leaders who have transformed the face of scientific research in the areas of redox biology and medicine.

Teich received the award in Boston on Nov. 20 during SFRBM 2015, the premier event for cutting-edge research in all aspects of redox biology. Seahorse was acquired by Agilent Technologies on Nov.

Agilent Technologies Inc. (NYSE: A) today introduced the 4200 TapeStation system, a fully automated instrument that enables scientists to rapidly analyze up to 96 DNA samples at a time.

"We designed the new instrument —the successor to our popular 2200 TapeStation system—to address the need for both higher throughput and higher quality in next-generation sequencing labs," said Knut Wintergerst, Marketing and Support manager for Agilent`s microfluidics product line.

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced the U.S. Food and Drug Administration has approved a new test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with OPDIVO® (nivolumab) for patients with non-squamous NSCLC.

Dako developed the diagnostic, known as PD-L1 IHC 28-8 pharmDx, through a collaboration with

Agilent Technologies Inc. (NYSE: A) is sharing its vision for precision medicine this week at the annual meeting of the American Society of Human Genomics. The conference, held in Baltimore, Maryland, is a forum for discussing recent advances in all areas of human genetics.

"As new technologies and greater understanding of the causes and pathways of diseases are moving through the research-clinical continuum, they are driving a revolution in precision medicine-a revolution that is ena

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced the U.S. Food and Drug Administration (FDA) approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer (NSCLC) is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako`s portfolio of companion diagnostics and the company`s leadership position in developing and commercializing com

Agilent Technologies Inc. (NYSE: A) announced today that Dr. Lawrence J. Lesko has received an Agilent Thought Leader Award in support of his research into preclinical toxicological assessments of new medicines.

An internationally recognized pharmacologist, Dr. Lesko directs the Center for Pharmacometrics and Systems Pharmacology at the University of Florida`s College of Pharmacy in Orlando.

"We are pleased to support Dr. Lesko`s research, which is addressing important needs i

Agilent Technologies Inc. (NYSE: A) today announced two additions to its AdvanceBio product family, designed to provide rapid, reproducible results for scientists in the biopharmaceutical industry.

Agilent introduced the products — the AdvanceBio glycan-mapping workflow and the AdvanceBio oligonucleotide column — at HPLC 2015, an international symposium being held in Geneva, Switzerland, this week.

"Both of these new products will help researchers achieve faster, m

Agilent Technologies Inc. (NYSE: A) today announced updates to its SurePrint gene expression microarrays for messenger RNA profiling applications for human, mouse and rat models. The updates improve coding and noncoding content, which will provide up-to-date tools for researchers to investigate expression patterns on a highly accessible platform.

Agilent developed the updates to its flagship SurePrint G3 Human v3 gene expression microarray in collaboration with Ghent University for co